Ludwig Fischer von Weikersthal
Overview
Explore the profile of Ludwig Fischer von Weikersthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2689
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stintzing S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, Kaiser F, Heinrich K, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401174.
PMID: 39903881
Purpose: The FIRE-4 study randomly assigned patients with first-line wild-type (wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity...
2.
Stahler A, Karthaus M, Fruehauf S, Graeven U, Muller L, Fischer von Weikersthal L, et al.
EClinicalMedicine
. 2025 Jan;
79():103004.
PMID: 39802302
Background: The PanaMa trial aimed to compare the efficacy of 5-fluorouracil and folinic acid (FU/FA) ± panitumumab maintenance in untreated wild-type metastatic colorectal cancer (mCRC) patients. Methods: In this final...
3.
Ettrich T, Modest D, Sinn M, Striefler J, Opitz B, Goetze T, et al.
J Clin Oncol
. 2024 Jun;
42(26):3094-3104.
PMID: 38843469
Purpose: First-line therapy options in advanced cholangiocarcinoma (CCA) are based on the ABC-02 trial regimen (gemcitabine/cisplatin [G/C]). The NIFE trial examined nanoliposomal irinotecan/fluorouracil/leucovorin (nal-IRI/FU/LV) as alternative first-line therapy in advanced...
4.
Heuschkel G, Fischer von Weikersthal L, Junghans C, Zomorodbakhsch B, Stoll C, Prott F, et al.
Oncol Res Treat
. 2024 Feb;
47(4):123-134.
PMID: 38325341
Introduction: Cancer diagnoses are constantly increasing in clinical practice. Therefore, more and more patients are interested in how they can actively participate in the process of treatment. Spirituality represents a...
5.
Stahler A, Kind A, Sers C, Mamlouk S, Muller L, Karthaus M, et al.
Clin Cancer Res
. 2024 Jan;
30(7):1256-1263.
PMID: 38289994
Purpose: We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid...
6.
Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Muller L, Konig A, et al.
Eur J Cancer
. 2023 Jul;
190:112955.
PMID: 37454537
Background: The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with...
7.
Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, et al.
Hemasphere
. 2023 Jul;
7(7):e904.
PMID: 37427146
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18-60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index...
8.
Dorman K, Boeck S, Snijder R, Siveke J, Schenk M, Mayerle J, et al.
Curr Oncol
. 2023 Jun;
30(6):5828-5834.
PMID: 37366919
This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the "Burden of Therapy" (BOTh) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients...
9.
Stintzing S, Heinrich K, Tougeron D, Modest D, Schwaner I, Eucker J, et al.
J Clin Oncol
. 2023 Jun;
41(25):4143-4153.
PMID: 37352476
Purpose: mutation is associated with a poor outcome in metastatic colorectal cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined with...
10.
Stahler A, Hoppe B, Na I, Keilholz L, Muller L, Karthaus M, et al.
J Clin Oncol
. 2023 Apr;
41(16):2975-2987.
PMID: 37018649
Purpose: Consensus molecular subtypes (CMSs) were evaluated as prognostic and predictive biomarkers of patients with wild-type metastatic colorectal cancer (mCRC) receiving fluorouracil and folinic acid (FU/FA) with or without panitumumab...